pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Apr 23·1 min read
save

Amgen Announces Retirement of Chief Technology Officer David Reese

Apr 23, 2026·read at Endpoints ↗Neutral

Amgen announced that longtime leader David Reese will retire at the end of June.

Reese, 63, currently serves as the company's chief technology officer, a position he created in 2023 after many years at the firm.

The company did not provide details on his successor or the transition plan.

His departure signals a leadership change for Amgen as it continues to advance its pipeline and technology initiatives.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “David Reese to retire from Amgen”

read at Endpoints ↗
85 words · retrieved Apr 26
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
AMGEN7

related stories

  • Jun 5Study data convince Lundbeck to push new migraine drug forwardBioPharma Dive
  • Jun 4STAT+: Does Revolution Medicines’ pancreatic cancer drug have even greater potential?STAT
  • May 29Bristol Myers unveils data for one of its next-gen blood cancer drugsBioPharma Dive
  • May 18Amgen stands by rare disease drug Tavneos amid Japan liver toxicity reportEndpoints
  • May 18Høeg fired in latest FDA shakeup; 20 people die after taking Amgen drugBioPharma Dive